Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values

Table 1 Characteristics of the patients presenting and not presenting post-rituximab IgG hypogammaglobulinemia

	Presenting IgG hypogammaglobulinemia, n = 11	Not presenting IgG hypogammaglobulinemia, n = 9	P-value
Age at NS onset, yr	2.8 (1.1)	5.2 (4.7)	0.07
Female sex n (%)	0 (0)	3 (33.3)	0.1
Corticosteroids n (%)	11 (100)	9 (100)	> 0.99
Corticosteroids (mean ± SD, mo)	76.5 ± 54.2	73.2 ± 30.9	0.87
Cyclosporine n (%)	11 (100)	9 (100)	> 0.99
Cyclosporine (mean ± SD, mo)	56.1 ± 23.1	66.4 ± 40.0	0.48
Cyclophosphamide n (%)	8 (72.3)	6 (66.7)	0.9
Cyclophosphamide (mean ± SD, mo)	3 ± 0.27	3 ± 0.33	0.9
Other immunosuppressive agents n (%)	2 (0.2)	3 (0.33)	0.43
> 1 immunosuppressive agents n (%)	8 (72.3)	7 (77.8)	0.43
Relapses (mean ± SD)	11.5 ± 4.6	16.5 ± 9.7	0.15
Relapses after first RTX infusion (mean ± SD)	1.6 ± 1.5	3.9 ± 4.6	0.15
RTX infusions (mean ± SD)	3.3 ± 1.8	5.0 ± 2.7	0.11
Age at first RTX infusion, (mean ± SD, yr)	9.2 ± 1.8	11.8 ± 4.5	0.09
Months of CD19-positive cells depletion (mean ± SD)	6.4 ± 3	6.2 ± 2.6	0.9
Months of follow-up after the last RTX infusion (mean ± SD)	31.1 ± 14.9	27.4 ± 20.7	0.59

RTX: Rituximab; IgG: Immunoglobulin G; NS: Nephrotic syndrome; SD: Standard deviation.